Bo Lu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11514940/publications.pdf

Version: 2024-02-01

		81900	46799
93 papers	14,272 citations	39 h-index	89 g-index

93 all docs	93 docs citations	93 times ranked	27278 citing authors

#	Article	IF	Citations
1	The incidence of atrial fibrillation shortly following radiation therapy in patients with lung cancer: A population-based study.. Journal of Clinical Oncology, 2022, 40, e18796-e18796.	1.6	1
2	Stereotactic body radiation therapy (SBRT) for patients with stage I non-small cell lung cancer is applicable to more tumors than sublobar resection. Journal of Thoracic Disease, 2021, 13, 1576-1583.	1.4	3
3	NBTXR3 Radiotherapy-Activated Functionalized Hafnium Oxide Nanoparticles Show Efficient Antitumor Effects Across a Large Panel of Human Cancer Models. International Journal of Nanomedicine, 2021, Volume 16, 2761-2773.	6.7	30
4	Addition of Metformin to Concurrent Chemoradiation in Patients With Locally Advanced Nonâ€“Small Cell Lung Cancer. JAMA Oncology, 2021, 7, 1324.	7.1	53
5	A Pilot Study of Radiation Therapy in Combination With Pembrolizumab in Patients With Metastatic Renal Cell Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 82-86.	1.3	5
6	Proposal of organ-specific subdivision of M component and staging system for metastatic pulmonary neuroendocrine tumor. Lung Cancer, 2020, 148, 86-93.	2.0	0
7	Impact of Sarcopenia on Survival in Patients With Early-Stage Lung Cancer Treated With Stereotactic Body Radiation Therapy. Cureus, 2020, 12, e10712.	0.5	5
8	Synergistic effect of immunotherapy and radiotherapy in non-small cell lung cancer: current clinical trials and prospective challenges. Precision Clinical Medicine, 2019, 2, 57-70.	3.3	24
9	Disparity in age at lung cancer diagnosis between current and former smokers. Journal of Cancer Research and Clinical Oncology, 2019, 145, 1243-1251.	2.5	7
10	Combining Radiation and Immune Checkpoint Blockade in the Treatment of Head and Neck Squamous Cell Carcinoma. Frontiers in Oncology, 2019, 9, 122.	2.8	63
11	SMAC Mimetic Debio 1143 and Ablative Radiation Therapy Synergize to Enhance Antitumor Immunity against Lung Cancer. Clinical Cancer Research, 2019, 25, 1113-1124.	7.0	25
12	Beyond Concurrent Chemoradiation: The Emerging Role of PD-1/PD-L1 Inhibitors in Stage III Lung Cancer. Clinical Cancer Research, 2018, 24, 1271-1276.	7.0	32
13	PD-1 Modulates Radiation-Induced Cardiac Toxicity through Cytotoxic T Lymphocytes. Journal of Thoracic Oncology, 2018, 13, 510-520.	1.1	77
14	Targeting Myeloid-derived Suppressor Cells and Programmed Death Ligand 1 Confers Therapeutic Advantage of Ablative Hypofractionated Radiation Therapy Compared With Conventional Fractionated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 101, 74-87.	0.8	82
15	Blockade of Tumor-Expressed PD-1 promotes lung cancer growth. OncoImmunology, 2018, 7, e1408747.	4.6	99
16	Neoadjuvant PD-1 blockade in non-small cell lung cancer: what else do we need to do?. Journal of Thoracic Disease, 2018, 10, S3162-S3165.	1.4	0
17	Utility of stereotactic ablative radiotherapy/stereotactic body radiation therapy in the setting of oligometastatic non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, 657-660.	1.4	6
18	Nivolumab plus cisplatin/pemetrexed or cisplatin/gemcitabine as induction in resectable NSCLC.. Journal of Clinical Oncology, 2018, 36, TPS8582-TPS8582.	1.6	2

#	Article	IF	Citations
19	siRNA-Encapsulated Hybrid Nanoparticles Target Mutant K-ras and Inhibit Metastatic Tumor Burden in a Mouse Model of Lung Cancer. Molecular Therapy - Nucleic Acids, 2017, 6, 259-268.	5.1	14
20	Comparison of Online 6 Degree-of-Freedom Image Registration of Varian TrueBeam Cone-Beam CT and BrainLab ExacTrac X-Ray for Intracranial Radiosurgery. Technology in Cancer Research and Treatment, 2017, 16, 339-343.	1.9	11
21	IGFBP3 Modulates Lung Tumorigenesis and Cell Growth through IGF1 Signaling. Molecular Cancer Research, 2017, 15, 896-904.	3.4	56
22	Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Nonâ€“Small-Cell Lung Cancer (RTOG 3505). Clinical Lung Cancer, 2017, 18, 333-339.	2.6	47
23	Decreased Survival After Combining Thoracic Irradiation and an Anti-PD-1 Antibody Correlated With Increased T-cell Infiltration Into Cardiac and Lung Tissues. International Journal of Radiation Oncology Biology Physics, 2017, 99, 1129-1136.	0.8	27
24	Randomized phase III trial of concurrent chemoradiation followed by nivolumab or placebo for locally advanced non-small cell lung cancer (NSCLC) (RTOG 3505).. Journal of Clinical Oncology, 2017, 35, TPS8579-TPS8579.	1.6	7
25	An exploratory study to investigate the immunomodulatory activity of radiation therapy in combination with pembrolizumab in patients with renal cell cancer.. Journal of Clinical Oncology, 2017, 35, e16058-e16058.	1.6	2
26	Lung cancer screening: not all nodules are created equal. Journal of Thoracic Disease, 2016, 8, E1257-E1259.	1.4	2
27	Systemic therapy for echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase non-small cell lung cancer brain metastases. Journal of Thoracic Disease, 2016, 8, E1028-E1031.	1.4	0
28	Stereotactic Body Radiation Therapy Delivery inÂaÂGenetically Engineered Mouse Model ofÂLungÂCancer. International Journal of Radiation Oncology Biology Physics, 2016, 96, 529-537.	0.8	14
29	Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy. Journal of Hematology and Oncology, 2016, 9, 96.	17.0	21
30	Biodistribution and Pharmacokinetics Study of siRNA-loaded Anti-NTSR1-mAb-functionalized Novel Hybrid Nanoparticles in a Metastatic Orthotopic Murine Lung Cancer Model. Molecular Therapy - Nucleic Acids, 2016, 5, e282.	5.1	14
31	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
32	Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Nonâ€“Small Cell Lung Cancers In Vitro and In Vivo. Clinical Cancer Research, 2016, 22, 122-133.	7.0	83
33	Nitrilase 1 modulates lung tumor progression in vitro and in vivo. Oncotarget, 2016, 7, 21381-21392.	1.8	5
34	BH3 mimetic ABT-737 sensitizes colorectal cancer cells to ixazomib through MCL-1 downregulation and autophagy inhibition. American Journal of Cancer Research, 2016, 6, 1345-57.	1.4	7
35	Targeting brain metastases in ALK-rearranged non-small-cell lung cancer. Lancet Oncology, The, 2015, 16, e510-e521.	10.7	160
36	Evaluation of Elekta 4D cone beam CT-based automatic image registration for radiation treatment of lung cancer. British Journal of Radiology, 2015, 88, 20140620.	2.2	14

#	Article	IF	Citations
37	Predicting overall survival for patients with periampullary carcinoma.. Journal of Clinical Oncology, 2015, 33, 376-376.	1.6	0
38	A Novel Radiation-Induced p53 Mutation Is Not Implicated in Radiation Resistance via a Dominant-Negative Effect. PLoS ONE, 2014, 9, e87492.	2.5	3
39	NVP-BEZ-235 enhances radiosensitization via blockade of the PI3K/mTOR pathway in cisplatin-resistant non-small cell lung carcinoma.. Genes and Cancer, 2014, 5, 293-302.	1.9	40
40	Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer. Journal of Thoracic Disease, 2014, 6, 387-98.	1.4	23
41	Assessment of M867, a selective caspase-3 inhibitor, in an orthotopic mouse model for non-small cell lung carcinoma. American Journal of Cancer Research, 2014, 4, 161-71.	1.4	5
42	Debio 1143, an antagonist of multiple inhibitor-of-apoptosis proteins, activates apoptosis and enhances radiosensitization of non-small cell lung cancer cells in vitro. American Journal of Cancer Research, 2014, 4, 943-51.	1.4	9
43	ALDH7A1 expression is associated with recurrence in patients with surgically resected non-small-cell lung carcinoma. Future Oncology, 2013, 9, 737-745.	2.4	25
44	Opportunities and Challenges in the Era of Molecularly Targeted Agents and Radiation Therapy. Journal of the National Cancer Institute, 2013, 105, 686-693.	6.3	40
45	ALK Inhibitor PF02341066 (Crizotinib) Increases Sensitivity to Radiation in Nonâ€“Small Cell Lung Cancer Expressing EML4-ALK. Molecular Cancer Therapeutics, 2013, 12, 696-704.	4.1	55
46	Molecular Profiling to Optimize Treatment in Non-Small Cell Lung Cancer: A Review of Potential Molecular Targets for Radiation Therapy by the Translational Research Program of the Radiation Therapy Oncology Group. International Journal of Radiation Oncology Biology Physics, 2012, 83, e453-e464.	0.8	34
47	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
48	No evidence for association of the MDM2-309 T/G promoter polymorphism with prostate cancer outcomes. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 319-323.	1.6	10
49	Cancer Stem Cells. Journal of Oncology, 2011, 2011, 1-1.	1.3	4
50	Terameprocol (Tetra-O-Methyl Nordihydroguaiaretic Acid), an Inhibitor of Sp1-Mediated Survivin Transcription, Induces Radiosensitization in Non-small Cell Lung Carcinoma. Journal of Thoracic Oncology, 2011, 6, 8-14.	1.1	30
51	BV6, an IAP Antagonist, Activates Apoptosis and Enhances Radiosensitization of Non-small Cell Lung Carcinoma In Vitro. Journal of Thoracic Oncology, 2011, 6, 1801-1809.	1.1	33
52	The Zinc Ionophore PCI-5002 Radiosensitizes Non-small Cell Lung Cancer Cells by Enhancing Autophagic Cell Death. Journal of Thoracic Oncology, 2011, 6, 1542-1552.	1.1	22
53	Inhibition of JAK2 Signaling by TG101209 Enhances Radiotherapy in Lung Cancer Models. Journal of Thoracic Oncology, 2011, 6, 699-706.	1.1	52
54	The Matrix Metalloproteinase-7 Polymorphism Rs10895304 Is Associated With Increased Recurrence Risk in Patients With Clinically Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1330-1335.	0.8	14

#	Article	IF	Citations
55	A Novel Bioluminescence Orthotopic Mouse Model for Advanced Lung Cancer. Radiation Research, 2011, 176, 486-493.	1.5	15
56	AT-101, a Pan-Bcl-2 Inhibitor, Leads to Radiosensitization of Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 680-687.	1.1	40
57	The EGFR Polymorphism rs884419 is Associated With Freedom From Recurrence in Patients With Resected Prostate Cancer. Journal of Urology, 2010, 183, 2062-2069.	0.4	20
58	Progress in the unraveling of the endoplasmic reticulum stress/autophagy pathway and cancer: Implications for future therapeutic approaches. Drug Resistance Updates, 2010, 13, 79-86.	14.4	100
59	Synergy between phosphatidylinositol 3-kinase/Akt pathway and Bcl-xL in the control of apoptosis in adenocarcinoma cells of the lung. Molecular Cancer Therapeutics, 2009, 8, 101-109.	4.1	66
60	HSP90 Inhibitors: Multi-Targeted Antitumor Effects and Novel Combinatorial Therapeutic Approaches in Cancer Therapy. Current Medicinal Chemistry, 2009, 16, 3081-3092.	2.4	60
61	Radiosensitization of solid tumors by Z-VAD, a pan-caspase inhibitor. Molecular Cancer Therapeutics, 2009, 8, 1270-1279.	4.1	41
62	Combined Bcl-2/Mammalian Target of Rapamycin Inhibition Leads to Enhanced Radiosensitization via Induction of Apoptosis and Autophagy in Nonâ€“Small Cell Lung Tumor Xenograft Model. Clinical Cancer Research, 2009, 15, 6096-6105.	7.0	108
63	Regulated cell death pathways: New twists in modulation of BCL2 family function. Molecular Cancer Therapeutics, 2009, 8, 1421-1429.	4.1	79
64	Chapter 14 Autophagy in Lung Cancer. Methods in Enzymology, 2009, 453, 287-304.	1.0	22
65	Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy, 2008, 4, 151-175.	9.1	2,064
66	Autophagy upregulation by inhibitors of caspase-3 and mTOR enhances radiotherapy in a mouse model of lung cancer. Autophagy, 2008, 4, 659-668.	9.1	162
67	M867, a Novel Selective Inhibitor of Caspase-3 Enhances Cell Death and Extends Tumor Growth Delay in Irradiated Lung Cancer Models. PLoS ONE, 2008, 3, e2275.	2.5	43
68	Crosstalk Between Bak/Bax and mTOR Signaling Regulates Radiation-Induced Autophagy. Autophagy, 2007, 3, 142-144.	9.1	77
69	Impact of inhomogeneity corrections on dose coverage in the treatment of lung cancer using stereotactic body radiation therapy. Medical Physics, 2007, 34, 2985-2994.	3.0	78
70	Cytoplasmic Clusterin Expression Is Associated with Longer Survival in Patients with Resected Nonâ€“Small Cell Lung Cancer. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1845-1851.	2.5	41
71	Switch Between Apoptosis and Autophagy: Radiation-Induced Endoplasmic Reticulum Stress?. Cell Cycle, 2007, 6, 793-798.	2.6	134
72	The Role of mTOR Inhibition in Augmenting Radiation Induced Autophagy. Technology in Cancer Research and Treatment, 2007, 6, 443-447.	1.9	29

#	Article	IF	Citations
73	Inhibition of Poly(ADP-Ribose) Polymerase Enhances Cell Death and Improves Tumor Growth Delay in Irradiated Lung Cancer Models. Clinical Cancer Research, 2007, 13, 3033-3042.	7.0	257
74	Autophagy signaling in cancer and its potential as novel target to improve anticancer therapy. Drug Resistance Updates, 2007, 10, 135-143.	14.4	113
75	Deep-inspiration breath-hold kilovoltage cone-beam CT for setup of stereotactic body radiation therapy for lung tumors: Initial experience. Lung Cancer, 2007, 56, 77-88.	2.0	45
76	Inhibition of Survivin and Aurora B Kinase Sensitizes Mesothelioma Cells by Enhancing Mitotic Arrests. International Journal of Radiation Oncology Biology Physics, 2007, 67, 1519-1525.	0.8	34
77	ATM polymorphism IVS62+60G>A is not associated with disease aggressiveness in prostate cancer. Urology, 2006, 67, 1320-1323.	1.0	10
78	E-cadherin promoter polymorphisms are not associated with the aggressiveness of prostate cancer in Caucasian patients. Urologic Oncology: Seminars and Original Investigations, 2006, 24, 496-502.	1.6	4
79	Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Molecular Cancer Therapeutics, 2006, 5, 1183-1189.	4.1	166
80	Inhibition of Mammalian Target of Rapamycin or Apoptotic Pathway Induces Autophagy and Radiosensitizes PTEN Null Prostate Cancer Cells. Cancer Research, 2006, 66, 10040-10047.	0.9	321
81	Inhibition of signal transducer and activator of transcription 3 activity results in down-regulation of Survivin following irradiation. Molecular Cancer Therapeutics, 2006, 5, 2659-2665.	4.1	49
82	Autophagy for Cancer Therapy through Inhibition of Pro-apoptotic Proteins and Mammalian Target of Rapamycin Signaling. Journal of Biological Chemistry, 2006, 281, 36883-36890.	3.4	162
83	Clusterin as a therapeutic target for radiation sensitization in a lung cancer model. International Journal of Radiation Oncology Biology Physics, 2005, 63, 1228-1236.	0.8	32
84	Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene, 2005, 24, 5414-5422.	5.9	182
85	Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma. Cancer, 2005, 103, 1685-1692.	4.1	92
86	Murine double minute 2 as a therapeutic target for radiation sensitization of lung cancer. Molecular Cancer Therapeutics, 2005, 4, 1137-1145.	4.1	10
87	The Use of Tyrosine Kinase Inhibitors in Modifying the Response of Tumor Microvasculature to Radiotherapy. Technology in Cancer Research and Treatment, 2005, 4, 691-698.	1.9	16
88	The Use of Gene Therapy in Cancer Research and Treatment. Technology in Cancer Research and Treatment, 2004, 3, 479-490.	1.9	13
89	Survivin As a Therapeutic Target for Radiation Sensitization in Lung Cancer. Cancer Research, 2004, 64, 2840-2845.	0.9	146
90	XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene, 2004, 23, 7047-7052.	5.9	160

#	Article	IF	Citations
91	The use of antisense oligonucleotides in evaluating survivin as a therapeutic target for radiation sensitization in lung cancer. Biological Procedures Online, 2004, 6, 250-256.	2.9	16
92	Broad spectrum receptor tyrosine kinase inhibitor, SU6668, sensitizes radiation via targeting survival pathway of vascular endothelium. International Journal of Radiation Oncology Biology Physics, 2004, 58, 844-850.	0.8	24
93	Low Temperature Induced Synthesis of TiN Nanocrystals. Inorganic Chemistry, 2004, 43, 3558-3560.	4.0	21